EarlyCDT®-Breast Frequently Asked Questions section
Here are answers to some frequently asked questions about the EarlyCDT®-Breast test.
Please do not forget to go through general EarlyCDT® FAQ section.
What is the recommended follow-up for a positive EarlyCDT®-Breast?
The recommended treatment/follow-up is described in the EarlyCDT® Patient Education Guide on page 8. If you do not have a Patient Guide, please click here to download.
To order additional Patient Education Guides for your office, please contact Client Services at 888-583-9030 to place your order.
Why should patients be examined for breast cancer with both EarlyCDT®-Breast and mammography?
EarlyCDT®-Breast is designed to be used in conjunction with other testing to be most effective. Mammography can only determine the outcome at the time of the test. Using mammography by itself only reduces fatality by 23%.* EarlyCDT® is recommended annually with a patient's mammogram to increase the likelihood of early detection.
*Source: Chapman, C., et al. Autoantibodies in Breast Cancer: Their Use as an Aid to Early Diagnosis. Annals of Oncology. 18:868-873, March 2007 (online publication).
Who should be examined for breast cancer using both EarlyCDT®-Breast and mammography?
Women of any age might benefit from a combination of EarlyCDT®-Breast and mammography. However, it is most often recommended for women aged 55 or under who have one or more of the risk factors for breast cancer.
The requisition form asks for oral contraceptives; however, there are forms of contraceptives with estrogen/progestogen that could be considered. Should patients select the box anyway? Yes. Women taking any form of estrogen/progestogen contraceptive should select the oral contraceptive box. The term is used because it is the most widely recognized form of hormonal birth control. Other forms that could be considered are NuvaRing®, Depo-Provera®, and Norplant®.
Does EarlyCDT®-Breast indicate the type of breast cancer present?
At this time, EarlyCDT® suggests only that breast cancer is present. It does not differentiate among types of breast cancer.
Does EarlyCDT®-Breast indicate other types of cancer might be present?
EarlyCDT®-Breast has been developed for use based on clinical histories that rule out other cancers.
Who benefits from the Oncimmune® EarlyCDT® -Breast?
Women answering “yes” to one or more of the questions in the breast cancer risk models, such as the Gail Model, should talk to their physician about their risk of developing breast cancer. The models can be found on the National Cancer Institute's website at:
www.cancer.gov or American Cancer Society at www.cancer.org.